Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet

Full article: New pharmacotherapeutic options for oral

Treatment Effect on Stroke Subtypes According to TOAST (Trial of

News at XI: moving beyond factor Xa inhibitors - ScienceDirect

Antithrombotic Therapy for Primary and Secondary Prevention of

Design and Preclinical Characterization Program toward Asundexian

Design and Preclinical Characterization Program toward Asundexian

Thromboinflammatory challenges in stroke pathophysiology

JCDD, Free Full-Text

Effects of Tablet Formulation, Food, or Gastric pH on the

PDF) Efficacy and Safety of Oral Factor XIa Inhibitors in Stroke

Ischaemic stroke despite antiplatelet therapy: Causes and outcomes

Dual Antiplatelet Therapies and Causes in Minor Stroke or

(BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site

Asundexian

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double